Insider Trading Alert - GPI, VRTX, ICON, FCS And IMPV Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Nov. 19, 2013, 167 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $93.28 to $173,250,000.00.

Highlighted Stocks Traded by Insiders:

Group 1 Automotive (GPI) - FREE Research Report

DeLongchamps Peter C who is VP, Financial Svcs/Mfr Rel at Group 1 Automotive sold 6,999 shares at $66.00 on Nov. 19, 2013. Following this transaction, the VP, Financial Svcs/Mfr Rel owned 47,895 shares meaning that the stake was reduced by 12.75% with the 6,999 share transaction.

The shares most recently traded at $65.98, down $0.02, or 0.03% since the insider transaction. Historical insider transactions for Group 1 Automotive go as follows:

  • 12-Week # shares sold: 3,148
  • 24-Week # shares sold: 5,540

The average volume for Group 1 Automotive has been 386,600 shares per day over the past 30 days. Group 1 Automotive has a market cap of $1.6 billion and is part of the services sector and specialty retail industry. Shares are up 6.57% year to date as of the close of trading on Tuesday.

Group 1 Automotive, Inc., through its subsidiaries, operates in the automotive retail industry. It sells new and used cars, light trucks, and vehicle parts. The stock currently has a dividend yield of 1.03%. The company has a P/E ratio of 15.7. Currently there are 7 analysts that rate Group 1 Automotive a buy, 1 analyst rates it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on GPI - FREE

TheStreet Quant Ratings rates Group 1 Automotive as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, reasonable valuation levels, good cash flow from operations, increase in stock price during the past year and increase in net income. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full Group 1 Automotive Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Vertex Pharmaceuticals (VRTX) - FREE Research Report

Connolly Thomas who is SVP, Human Resources at Vertex Pharmaceuticals sold 150 shares at $61.05 on Nov. 19, 2013. Following this transaction, the SVP, Human Resources owned 4,252 shares meaning that the stake was reduced by 3.41% with the 150 share transaction.

Pace Megan E who is SVP, Corp. Communications at Vertex Pharmaceuticals sold 93 shares at $60.97 on Nov. 19, 2013. Following this transaction, the SVP, Corp. Communications owned 17,271 shares meaning that the stake was reduced by 0.54% with the 93 share transaction.

The shares most recently traded at $64.61, up $3.64, or 5.63% since the insider transaction. Historical insider transactions for Vertex Pharmaceuticals go as follows:

  • 4-Week # shares sold: 9,050
  • 12-Week # shares sold: 38,067
  • 24-Week # shares sold: 60,208

The average volume for Vertex Pharmaceuticals has been 2.6 million shares per day over the past 30 days. Vertex Pharmaceuticals has a market cap of $14.4 billion and is part of the health care sector and drugs industry. Shares are up 47.23% year to date as of the close of trading on Tuesday.

Vertex Pharmaceuticals Incorporated engages in discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. Currently there are 12 analysts that rate Vertex Pharmaceuticals a buy, no analysts rate it a sell, and 8 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on VRTX - FREE

TheStreet Quant Ratings rates Vertex Pharmaceuticals as a sell. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income, disappointing return on equity and weak operating cash flow. Get the full Vertex Pharmaceuticals Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Iconix Brand Group (ICON) - FREE Research Report

Friedman Mark A who is Director at Iconix Brand Group sold 9,776 shares at $38.47 on Nov. 19, 2013. Following this transaction, the Director owned 39,925 shares meaning that the stake was reduced by 19.67% with the 9,776 share transaction.

The shares most recently traded at $37.62, down $0.85, or 2.26% since the insider transaction. Historical insider transactions for Iconix Brand Group go as follows:

  • 24-Week # shares sold: 7,815

The average volume for Iconix Brand Group has been 591,600 shares per day over the past 30 days. Iconix Brand Group has a market cap of $2.0 billion and is part of the consumer goods sector and consumer non-durables industry. Shares are up 72.04% year to date as of the close of trading on Tuesday.

Iconix Brand Group, Inc., a brand management company, engages in licensing, marketing, and providing trend direction for a portfolio of consumer and entertainment brands primarily in the United States, Canada, Japan, and Europe. The company has a P/E ratio of 18.8. Currently there are no analysts that rate Iconix Brand Group a buy, 1 analyst rates it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ICON - FREE

TheStreet Quant Ratings rates Iconix Brand Group as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, expanding profit margins, impressive record of earnings per share growth and increase in net income. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Iconix Brand Group Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Fairchild Semiconductor International (FCS) - FREE Research Report

Delva Paul D who is Senior Vice President at Fairchild Semiconductor International sold 17,000 shares at $12.46 on Nov. 19, 2013. Following this transaction, the Senior Vice President owned 57,815 shares meaning that the stake was reduced by 22.72% with the 17,000 share transaction.

The shares most recently traded at $12.36, down $0.10, or 0.81% since the insider transaction. Historical insider transactions for Fairchild Semiconductor International go as follows:

  • 12-Week # shares bought: 20,000
  • 12-Week # shares sold: 36,732
  • 24-Week # shares bought: 20,000
  • 24-Week # shares sold: 36,732

The average volume for Fairchild Semiconductor International has been 1.2 million shares per day over the past 30 days. Fairchild Semiconductor International has a market cap of $1.6 billion and is part of the technology sector and electronics industry. Shares are down 13.26% year to date as of the close of trading on Tuesday.

Fairchild Semiconductor International, Inc. designs, develops, manufactures, and sells power analog, power discrete, and non-power semiconductor solutions worldwide. Currently there are 4 analysts that rate Fairchild Semiconductor International a buy, no analysts rate it a sell, and 4 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on FCS - FREE

TheStreet Quant Ratings rates Fairchild Semiconductor International as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, disappointing return on equity and feeble growth in the company's earnings per share. Get the full Fairchild Semiconductor International Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Imperva (IMPV) - FREE Research Report

Shulman Amichai who is Chief Technology Officer at Imperva sold 235 shares at $39.43 on Nov. 19, 2013. Following this transaction, the Chief Technology Officer owned 10,000 shares meaning that the stake was reduced by 2.3% with the 235 share transaction.

Kraynak Mark E. who is Senior VP, Worldwide Marketing at Imperva sold 3,190 shares at $37.80 on Nov. 19, 2013. Following this transaction, the Senior VP, Worldwide Marketing owned 15,000 shares meaning that the stake was reduced by 17.54% with the 3,190 share transaction.

The shares most recently traded at $38.00, up $0.20, or 0.53% since the insider transaction. Historical insider transactions for Imperva go as follows:

  • 24-Week # shares sold: 750

The average volume for Imperva has been 304,600 shares per day over the past 30 days. Imperva has a market cap of $968.5 million and is part of the technology sector and computer software & services industry. Shares are up 21.22% year to date as of the close of trading on Tuesday.

Imperva, Inc. engages in the development, marketing, sale, service, and support of business security solutions that provide visibility and control over high value business data across critical systems within the data center. The company operates in two segments, Imperva and Incapsula. Currently there are 5 analysts that rate Imperva a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on IMPV - FREE

TheStreet Quant Ratings rates Imperva as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity, weak operating cash flow and feeble growth in its earnings per share. Get the full Imperva Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Data for this article provided by Zacks Investment Research

null

More from Markets

Week Ahead: Trade Fears and Stress Tests Signal More Volatility To Come

Week Ahead: Trade Fears and Stress Tests Signal More Volatility To Come

Trump Takes Aim at Auto Imports; Markets End Mixed -- ICYMI

Trump Takes Aim at Auto Imports; Markets End Mixed -- ICYMI

Video: What Oprah's Content Partnership With Apple Means for the Rest of Tech

Video: What Oprah's Content Partnership With Apple Means for the Rest of Tech

REPLAY: Jim Cramer on the Markets, Oil, Starbucks, Tesla, Okta and Red Hat

REPLAY: Jim Cramer on the Markets, Oil, Starbucks, Tesla, Okta and Red Hat

Flashback Friday: The Market Movers

Flashback Friday: The Market Movers